Trial Profile
A Double-Blind, Placebo-Controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2014
Price :
$35
*
At a glance
- Drugs Vidutolimod (Primary)
- Indications Allergic asthma; Hypersensitivity
- Focus Therapeutic Use
- 09 Sep 2013 Results from a post-hoc analysis of data published have been presented at the European Respiratory Society Annual Congress (ERS-2013) according to a Cytos Biotechnology media release. Results were also summarised in the media release.
- 12 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society.